TATDN2P3

Across TCGA pan-cancer cohorts, TATDN2P3 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated TATDN2P3 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TATDN2P3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TATDN2P3 expression acts as an unfavorable survival marker, although some lineages such as UCS and GBM show a favorable association.

LIHC, UCS, and THCA are the cancer types where TATDN2P3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	III,IV	0.149	0.441	.012	63	view →
UCS	DFS	Tertile	III,IV	0.561	0.168	.008	42	view →
THCA	OS	Tertile	II,III,IV	0.868	0.977	.001	41	view →
MESO	DFS	Tertile	III,IV	0.262	0.543	.002	33	view →
CHOL	DFS	Tertile	All	0.113	0.514	.027	27	view →
READ	OS	Tertile	III,IV	0.227	0.795	<.001	21	view →
GBM	OS	Median	All	0.511	0.347	.001	20	view →
HNSC	DFS	Median	III,IV	0.451	0.188	.010	11	view →
KIRP	OS	Median	III,IV	0.777	0.534	.027	9	view →
SARC	OS	Tertile	All	0.395	0.806	<.001	8	view →
LUSC	DFS	Median	All	0.704	0.615	.023	7	view →
SKCM	OS	Median	II,III,IV	0.443	0.274	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

TATDN2P3–LIHC (DFS)

Open the LIHC breakdown →